摘要
目的:初步评估华蟾素注射液肝动脉给药联合碘油栓塞治疗中晚期肝癌的安全性。方法:将住院治疗的中晚期原发性肝癌患者80例分为华蟾素组和表阿霉素组。两组患者均予肝动脉栓塞术(HAE)治疗,华蟾素组患者同时给予华蟾素注射液肝动脉注射,表阿霉素组给予表阿霉素肝动脉注射。分别于纳入时及3个月时进行介入,治疗方案结束后第6周进行疗效评价。检测患者血常规、肝肾功能、凝血功能指标并观察患者介入术后不良反应等,评价华蟾素治疗的安全性。结果:治疗前两组患者的血常规、肝肾功能、凝血指标等差异均无统计学差异(P>0.05)。介入术后两组患者均出现骨髓抑制现象,WBC、PLT和HGB下降,但华蟾素组轻于表阿霉素组。两组患者血TB、ALT、AST水平均显著升高(P<0.05,P<0.01),第6天开始恢复,在治疗后第6周华蟾素组TB、ALT、AST、ALP、γ-GGT值低于表阿霉素组(P<0.05)。两种治疗方法对肾功能及凝血指标无明显影响。华蟾素组患者出现厌食、恶心呕吐、发热、疼痛等症状的程度及例数明显低于表阿霉素组。结论:华蟾素注射液肝动脉栓塞治疗方案较表阿霉素肝动脉栓塞治疗方案具有较高的安全性。
Objective：To evaluate the safety of cinobufagin injection via hepatic artery combined with lipi- odol embolization for treatment of patients with intermediate or advanced liver cancer. Methods：Eighty pa- tients with intermediate or advanced primary liver cancer in the hospital were divided into cinobufagin group and epirubicin group. All patients accepted hepatic arterial embolization. Patients in cinobufagin group were given cinobufagin injection via hepatic artery and patients in epirubicin group were given epirubicin injection via hepatic artery. The treatment was given when the patients were enrolled and 3 months after the enrollment. The curative effect was evaluated from the 6th week after treatment. The routine blood test, liver and kidney functions,blood coagulation function and adverse reaction after embolization were detected for the evaluation of the safety of cinobufagin. Result：Before treatment,there were no significant differences among the indexes of routine blood test,liver and kidney functions and coagulation function of the two groups（P〉0.05）. After the operation,bone marrow suppression appeared in patients of both the two groups and the WBC,PLT and HGB reduced,but the condition of the cinobufagin group was better than that of the epirubicin group. The TB ,ALT and AST levels of patients in both the two groups increased signifi- cantly（P〈O.OS,P〈O.O1）,but they began to recover from the 6th day. In the 6th week after treatment,the levels of TB,ALT,AST,ALP and ^-GGT of the cinobufagin group were lower than those of the epirubicin group. The two treatments had no significant effect on kidney functions and coagulation indicators. The cas- es and degree of symptoms such as anorexia , nausea , vomit , fever , pain , etc. of the cinobufagin group were significantly less than those of the epirubicin group. Conclusion：cinobufagin injection via hepatic arterial embolization is safer than epirubicin injection via hepatic arterial embolization.
出处
《山东中医药大学学报》
2015年第3期226-230,共5页
Journal of Shandong University of Traditional Chinese Medicine
关键词
华蟾素注射液
表阿霉素
碘油
肝动脉给药
肝肿瘤
局部灌注
安全性评价
cinobufagin injection
epirubicin
lipiodol
medication via hepatic artery
liver tumor
regional perfusion
evaluation of safty
